Vistagen Completes Last Patient Visit in PALISADE-4 Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 08 2026
0mins
Vistagen announced that the last patient has completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Company's Phase 3 clinical trial evaluating fasedienol nasal spray for the acute treatment of social anxiety disorder. The open label extension portion of the PALISADE-4 study remains ongoing. PALISADE-4 is a U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical study designed to evaluate the efficacy, safety, and tolerability of a single dose of fasedienol in reducing anxiety symptoms in adults with social anxiety disorder during a simulated anxiety-provoking public speaking challenge conducted in a clinical setting using the Subjective Units of Distress Scale as the primary endpoint. Participants in the randomized portion of PALISADE-4 who chose to continue with the OLE portion of the study can use fasedienol in their daily lives up to six times per day for up to twelve months.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTGN
Wall Street analysts forecast VTGN stock price to rise
5 Analyst Rating
0 Buy
5 Hold
0 Sell
Hold
Current: 0.573
Low
0.90
Averages
0.97
High
1.00
Current: 0.573
Low
0.90
Averages
0.97
High
1.00
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VistaGen Therapeutics Reports FY Earnings with Revenue Surge
- Earnings Report: VistaGen Therapeutics reported a FY GAAP EPS of -$1.83, missing expectations by $0.06, indicating ongoing challenges in achieving profitability.
- Revenue Surge: The company achieved revenue of $1.27M, a remarkable 164.6% year-over-year increase, surpassing market expectations by $0.25M, which may lay the groundwork for future market expansion.
- Cash Reserves: As of March 31, 2026, VistaGen reported cash, cash equivalents, and marketable securities totaling $45.4 million, indicating a healthy liquidity position that can support operational needs moving forward.
- Funding Outlook: Based on current operating plans, VistaGen believes its cash reserves will be sufficient to fund operations into 2027, demonstrating confidence in future growth and potentially attracting more investor interest.
See More
Vistagen Achieves Key Milestone in Social Anxiety Drug Development
- Clinical Trial Progress: Vistagen's fasedienol nasal spray has surpassed ICH E1 standards in its clinical trials for social anxiety disorder, with over 1,500 subjects having received at least one treatment, 300 subjects completing 6 months, and 100 subjects completing 12 months of treatment, demonstrating good tolerability and safety.
- FDA Application Outlook: Although the minimum safety exposure requirements of ICH E1 have been met, Vistagen has not yet aligned with the FDA on specific patient exposure requirements for fasedienol, which may impact the timing and success of future NDA submissions.
- Expected Research Results: Topline results from the randomized, double-blind portion of PALISADE-4 are expected in Q2 2026, while results from the Phase 2 Repeat Dose study are anticipated in Q3 2026, providing critical data to support fasedienol's efficacy.
- Market Potential: With over 30 million adults affected by social anxiety disorder in the U.S., fasedienol represents a novel treatment option that could offer Vistagen significant market opportunities, especially given the limited current treatment options.
See More
Vistagen Therapeutics Faces Shareholder Lawsuit Investigation
- Shareholder Lawsuit Investigation: Kuehn Law, PLLC is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges the company failed to disclose risks associated with clinical trials for Social Anxiety Disorder.
- Clinical Trial Risks: The lawsuit claims that Vistagen's Phase 2 trials revealed that public speaking challenge endpoints often showed elevated placebo responses, site variability, and measurement noise, yet the company continued to assert modifications to the Phase 3 trial and presented PALISADE-3 as likely to succeed.
- Investor Rights Protection: Kuehn Law urges shareholders who purchased VTGN before April 1, 2024, to contact their attorney promptly to enforce their rights, emphasizing that shareholder voices are crucial for the integrity and fairness of financial markets.
- Legal Fee Commitment: Kuehn Law commits to covering all case costs without charging investor clients, highlighting its dedication to protecting shareholder interests and encouraging more shareholders to participate in the lawsuit to safeguard their investments.
See More
Vistagen Appoints New Chief Medical Officer
- Executive Appointment: Vistagen has appointed Dr. Angel S. Angelov as Chief Medical Officer, effective May 18, 2026, bringing two decades of experience in clinical development and medical affairs, which is expected to drive innovation in neuropsychiatry and women's health.
- Extensive Industry Background: Dr. Angelov has held significant roles at companies like Karuna, Neurocrine, Novartis, and Teva, and his expertise in neuromodulation therapeutics will provide crucial support for Vistagen's product development, particularly in treating acute social anxiety disorder and major depressive disorder.
- Incentive Measures: The Compensation Committee of Vistagen's Board granted Dr. Angelov an option to purchase 150,000 shares of common stock at an exercise price of $0.5955 per share, which is expected to incentivize his long-term contributions to the company and enhance team cohesion.
- Product Development Outlook: Vistagen's pherine product candidates aim to deliver therapeutic effects through intranasal administration, avoiding blood absorption, and if successfully developed, could offer safer treatment options for patients, particularly in managing social anxiety and menopausal symptoms.
See More
Vistagen CEO to Participate in Healthcare Conference
- Conference Participation: Vistagen's CEO Shawn Singh will participate in a fireside chat at the RBC Capital Markets Global Healthcare conference on May 20, 2026, at 2:35 p.m. Eastern Time, showcasing the company's pioneering research in neuroscience.
- One-on-One Meetings: The company will also host one-on-one meetings during the conference, aimed at deepening investor engagement and enhancing understanding and confidence in Vistagen's innovative approaches.
- Product Candidate Progress: Vistagen's leading product candidates include fasedienol for social anxiety disorder, itruvone for major depressive disorder, and refisolone for vasomotor symptoms, all in clinical development, indicating significant market potential.
- Technological Advantage: Vistagen's pherine candidates utilize intranasal delivery to achieve rapid onset without blood absorption, potentially offering safer treatment options for patients, which could transform existing therapeutic approaches if successfully developed.
See More
Positive Data on Fasedienol Nasal Spray for Social Anxiety Disorder
- Strong Safety Profile: In the open-label extension of the PALISADE-3 study, 341 patients with social anxiety disorder demonstrated a low discontinuation rate of 2.6% due to adverse events, with most being mild or moderate, indicating a favorable safety profile for fasedienol.
- Significant Clinical Improvement: Over four months of treatment, patients showed an average improvement of 25.4 points on the Liebowitz Social Anxiety Scale (LSAS), with 56% achieving a ≥20 point improvement, highlighting the clinical relevance of fasedienol in alleviating social anxiety.
- Positive Patient Feedback: Vistagen's CEO Shawn Singh noted that patients' ability to manage anxiety in daily life situations has significantly improved, underscoring the importance and potential market demand for fasedienol in real-world applications.
- Promising Future Research: Vistagen plans to release topline data from PALISADE-4 in Q2 2026, and if results are positive, it could provide substantial support for a New Drug Application (NDA) to the FDA, further advancing fasedienol's commercialization efforts.
See More
VistaGen Therapeutics Reports FY Earnings with Revenue Surge
- Earnings Report: VistaGen Therapeutics reported a FY GAAP EPS of -$1.83, missing expectations by $0.06, indicating ongoing challenges in achieving profitability.
- Revenue Surge: The company achieved revenue of $1.27M, a remarkable 164.6% year-over-year increase, surpassing market expectations by $0.25M, which may lay the groundwork for future market expansion.
- Cash Reserves: As of March 31, 2026, VistaGen reported cash, cash equivalents, and marketable securities totaling $45.4 million, indicating a healthy liquidity position that can support operational needs moving forward.
- Funding Outlook: Based on current operating plans, VistaGen believes its cash reserves will be sufficient to fund operations into 2027, demonstrating confidence in future growth and potentially attracting more investor interest.
See More
Vistagen Achieves Key Milestone in Social Anxiety Drug Development
- Clinical Trial Progress: Vistagen's fasedienol nasal spray has surpassed ICH E1 standards in its clinical trials for social anxiety disorder, with over 1,500 subjects having received at least one treatment, 300 subjects completing 6 months, and 100 subjects completing 12 months of treatment, demonstrating good tolerability and safety.
- FDA Application Outlook: Although the minimum safety exposure requirements of ICH E1 have been met, Vistagen has not yet aligned with the FDA on specific patient exposure requirements for fasedienol, which may impact the timing and success of future NDA submissions.
- Expected Research Results: Topline results from the randomized, double-blind portion of PALISADE-4 are expected in Q2 2026, while results from the Phase 2 Repeat Dose study are anticipated in Q3 2026, providing critical data to support fasedienol's efficacy.
- Market Potential: With over 30 million adults affected by social anxiety disorder in the U.S., fasedienol represents a novel treatment option that could offer Vistagen significant market opportunities, especially given the limited current treatment options.
See More
Vistagen Therapeutics Faces Shareholder Lawsuit Investigation
- Shareholder Lawsuit Investigation: Kuehn Law, PLLC is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges the company failed to disclose risks associated with clinical trials for Social Anxiety Disorder.
- Clinical Trial Risks: The lawsuit claims that Vistagen's Phase 2 trials revealed that public speaking challenge endpoints often showed elevated placebo responses, site variability, and measurement noise, yet the company continued to assert modifications to the Phase 3 trial and presented PALISADE-3 as likely to succeed.
- Investor Rights Protection: Kuehn Law urges shareholders who purchased VTGN before April 1, 2024, to contact their attorney promptly to enforce their rights, emphasizing that shareholder voices are crucial for the integrity and fairness of financial markets.
- Legal Fee Commitment: Kuehn Law commits to covering all case costs without charging investor clients, highlighting its dedication to protecting shareholder interests and encouraging more shareholders to participate in the lawsuit to safeguard their investments.
See More
Vistagen Appoints New Chief Medical Officer
- Executive Appointment: Vistagen has appointed Dr. Angel S. Angelov as Chief Medical Officer, effective May 18, 2026, bringing two decades of experience in clinical development and medical affairs, which is expected to drive innovation in neuropsychiatry and women's health.
- Extensive Industry Background: Dr. Angelov has held significant roles at companies like Karuna, Neurocrine, Novartis, and Teva, and his expertise in neuromodulation therapeutics will provide crucial support for Vistagen's product development, particularly in treating acute social anxiety disorder and major depressive disorder.
- Incentive Measures: The Compensation Committee of Vistagen's Board granted Dr. Angelov an option to purchase 150,000 shares of common stock at an exercise price of $0.5955 per share, which is expected to incentivize his long-term contributions to the company and enhance team cohesion.
- Product Development Outlook: Vistagen's pherine product candidates aim to deliver therapeutic effects through intranasal administration, avoiding blood absorption, and if successfully developed, could offer safer treatment options for patients, particularly in managing social anxiety and menopausal symptoms.
See More
Vistagen CEO to Participate in Healthcare Conference
- Conference Participation: Vistagen's CEO Shawn Singh will participate in a fireside chat at the RBC Capital Markets Global Healthcare conference on May 20, 2026, at 2:35 p.m. Eastern Time, showcasing the company's pioneering research in neuroscience.
- One-on-One Meetings: The company will also host one-on-one meetings during the conference, aimed at deepening investor engagement and enhancing understanding and confidence in Vistagen's innovative approaches.
- Product Candidate Progress: Vistagen's leading product candidates include fasedienol for social anxiety disorder, itruvone for major depressive disorder, and refisolone for vasomotor symptoms, all in clinical development, indicating significant market potential.
- Technological Advantage: Vistagen's pherine candidates utilize intranasal delivery to achieve rapid onset without blood absorption, potentially offering safer treatment options for patients, which could transform existing therapeutic approaches if successfully developed.
See More
Positive Data on Fasedienol Nasal Spray for Social Anxiety Disorder
- Strong Safety Profile: In the open-label extension of the PALISADE-3 study, 341 patients with social anxiety disorder demonstrated a low discontinuation rate of 2.6% due to adverse events, with most being mild or moderate, indicating a favorable safety profile for fasedienol.
- Significant Clinical Improvement: Over four months of treatment, patients showed an average improvement of 25.4 points on the Liebowitz Social Anxiety Scale (LSAS), with 56% achieving a ≥20 point improvement, highlighting the clinical relevance of fasedienol in alleviating social anxiety.
- Positive Patient Feedback: Vistagen's CEO Shawn Singh noted that patients' ability to manage anxiety in daily life situations has significantly improved, underscoring the importance and potential market demand for fasedienol in real-world applications.
- Promising Future Research: Vistagen plans to release topline data from PALISADE-4 in Q2 2026, and if results are positive, it could provide substantial support for a New Drug Application (NDA) to the FDA, further advancing fasedienol's commercialization efforts.
See More
